Biotech stocks offer potential high returns from developing drugs and therapies. Investing in biotech involves risks, such as clinical failures and regulatory hurdles. Diversified investment options ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

According to MarketsandMarkets™, the Wearables in Pharma & Biotech Market is projected to grow from about USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%.